NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD
Post# of 85
(Total Views: 112)
Posted On: 11/07/2023 3:47:23 PM
NetworkNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According to the announcement, the findings from the study were published in the “Annals of General Psychiatry.” The company noted that the research had been led by PaxMedica CMO Dr. David Hough, who worked with a team of renowned ASD specialists. The research was based on a comprehensive, 14-week randomized, double-blind, placebo-controlled study with 52 participants diagnosed with moderate to severe ASD; the participants were boys aged 4 to 15 years of age. The main focus of the study was to evaluate the efficacy and safety of suramin intravenous infusions, with the 10 mg/kg suramin arm demonstrating promising results in the improvement of core symptoms. According to the company, the study revealed statistically significant improvements in the Clinical Global Impressions-Improvement (“CGI-I”) scale among the 10 mg/kg arm compared to the placebo group. “We are highly encouraged by the findings of our study, which provide significant insights into the potential of suramin as a safe and effective treatment for the core symptoms of ASD,” said PaxMedica chief medical officer Dr. David Hough in the press release.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting that its phase 2 study research exploring the potential of low-dose suramin intravenous infusions as an autism spectrum disorder (“ASD”) treatment has been published. According to the announcement, the findings from the study were published in the “Annals of General Psychiatry.” The company noted that the research had been led by PaxMedica CMO Dr. David Hough, who worked with a team of renowned ASD specialists. The research was based on a comprehensive, 14-week randomized, double-blind, placebo-controlled study with 52 participants diagnosed with moderate to severe ASD; the participants were boys aged 4 to 15 years of age. The main focus of the study was to evaluate the efficacy and safety of suramin intravenous infusions, with the 10 mg/kg suramin arm demonstrating promising results in the improvement of core symptoms. According to the company, the study revealed statistically significant improvements in the Clinical Global Impressions-Improvement (“CGI-I”) scale among the 10 mg/kg arm compared to the placebo group. “We are highly encouraged by the findings of our study, which provide significant insights into the potential of suramin as a safe and effective treatment for the core symptoms of ASD,” said PaxMedica chief medical officer Dr. David Hough in the press release.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PaxMedica Inc. (PXMD) Stock Research Links
Scroll down for more posts ▼